Lupin’s arm completes divestiture of Kyowa to Unison

17 Dec 2019 Evaluate

Lupin’s subsidiary--Nanomi B.V. has completed the divestiture of the entire stake (99.82%) in Kyowa Pharmaceutical Industry (Kyowa) to Unison Capital Partners IV, LPS and Unison Capital Partners IV (F). L.P. (collectively referred to as ‘Unison’), pursuant to the satisfactory completion of all customary closing conditions. The divestiture which valued Kyowa at an Enterprise Value of JPY 57,361 million, was announced on November 11, 2019 and approved by Lupin’s shareholders.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2138.65 -12.40 (-0.58%)
01-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.20
Dr. Reddys Lab 1182.75
Cipla 1325.85
Zydus Lifesciences 878.80
Lupin 2138.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×